Some studies have shown that ankylosing spondylitis can take effect in the first week of using stockchildren’s monoclonal antibody, but there may be differences in the exact time of onset of effect after treatment with the drug, which may be related to the patient’s physical condition, disease and other factors.
Succizumab is a fully human monoclonal antibody with high affinity, which can inhibit the release of chemokines and pro-inflammatory factors, and is mainly used for the treatment of psoriasis and ankylosing spondylitis.
Patients with ankylosing spondylitis treated with Succizumab usually start to have an effect in the first week of administration, which can relieve the symptoms and spinal mobility of ankylosing spondylitis patients, but the exact time of onset of effect of patients treated with the drug may vary from one patient to another.
Ankylosing spondylitis patients can go to the rheumatology and immunology department of regular hospitals for detailed consultation. Follow the doctor’s instructions to standardize the treatment, do not self-medication.